Modafinil for the treatment of fatigue in lung cancer: a pilot study

Not Applicable

Completed

• Conditions: on small cell lung cancer; Cancer; Non small cell lung cancer

• Registration Number: ISRCTN82265570
• Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust (UK)

Brief Summary

2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19270033 results

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-04-24
• Study Completion: 2007-05-18
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 208

Inclusion Criteria

1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
2. A fatigue score of four using bimodal scoring in the Chalder fatigue scale
3. World Health Organisation (WHO) performance status of 0-3
4. Ability to give informed consent to participate

Exclusion Criteria

1. Received radiotherapy or chemotherapy within the last four weeks
2. Commenced on antidepressants or steroids (corticosteroids and progestational steroids) within the last two weeks
3. Received blood transfusion within the last two weeks
4. Potentially fertile women of child-bearing age
5. Uncontrolled moderate to severe hypertension, arrhythmia
6. Previous adverse reaction to modafinil or other central nervous system (CNS) stimulant
7. Current active involvement in another clinical trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in fatigue

Secondary Outcome Measures

Name	Time	Method
Change in sleepiness and depression levels